Forhøjelserne forekom oftest indenfor 6 til 12 uger efter behandlingens start og var ikke forbundet med nogen form for kliniske tegn eller symptomer.
The increases usually appeared within 6 to 12 weeks of starting treatment, and were not associated with any clinical signs or symptoms.